The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia
Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)
Advised the Special Committee of Brookfield Property Partners L.P., one of the world’s premier commercial real estate companies, on its repurchase of up to $890 million of publicly held units, funded with an equity investment from Brookfield Asset Management and its affiliates
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
Advised Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
Advised Australian Unity, an Australian healthcare, financial services and retirement and living services company, on the formation of a strategic 50:50 joint venture with Keppel for investment opportunities in the Australian metropolitan office property sector
Advised OurHealth, a provider of onsite and near-site employer-sponsored primary care clinics, on its sale to General Atlantic and merger with Marathon Health
Advised Dexus in relation to its acquisition of the 80 Collins precinct from QIC Global Real Estate
Advised T5 Data Centers, a leading national data center owner and operator, on the creation of a fully integrated platform with QuadReal Property Group to develop, acquire and operate data centers via a $1.0 billion investment from QuadReal
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
Advised Starpharma Holdings Limited on a U.S. licensing agreement of its patented VivaGel BV® product with ITF Pharma, a U.S. subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
Advised Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
Advising Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
Advised CatchMark Timber Trust, Inc. on its purchase of 1.1 million acres of East Texas timberlands from Campbell Global
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
Advised the Special Committee of the Board of Trustees of Pure Industrial Real Estate Trust ("PIRET"), the largest pure-play industrial REIT in Canada, regarding the acquisition of PIRET by Blackstone Property Partners
Advised Ladbrokes Coral Group PLC, a leading multi-channel sports betting and gaming company, on a recommended offer from GVC Holdings PLC, a multi-national online sports betting and gaming company
Advised the shareholders of Grupo Sidecu, the leading concessional sport center operator in Spain, on its sale of a controlling stake to Portobello Capital, a local private equity fund
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
Advised selected Second Lien Noteholders, including Canyon Capital Advisors, Mason Capital, Paulson & Co. and Soros Fund Management regarding Caesars Entertainment Operating Company’s Chapter 11 proceedings
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology
Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the U.S. rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 42 generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 2 generic drug products to Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 8 generic drug products to Dr. Reddy’s Laboratories
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
Advised Recepta Biopharma on a capital raise
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
Advised Ladbrokes plc, a leading UK betting and gaming company, on the recommended all-share merger with certain businesses of Gala Coral Limited, including Coral Retail, Eurobet Retail and Gala Coral Online
Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare
Provided Fairness Opinion to the Transaction Committee of the Board of Directors of New Senior Investment Group, a $2.5 billion publicly traded REIT, on its acquisition of a 28-property portfolio from Holiday Retirement, one of the largest private operators of senior housing in the U.S.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
Advised Telecity Group plc, Europe’s leading provider of premium carrier-neutral data centres, on a recommended cash and share offer from Equinix, Inc. a leading U.S. provider of colocation data centre services globally
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
Advised TUI AG on the merger with TUI Travel Plc creating the world’s number one integrated leisure tourism business (+Transaction value represents enterprise value of combined entity)
Advised MGM Resorts International on the formation of a joint venture hotel management company with the Hakkasan Group called MGM Hakkasan Hospitality that will design, develop and manage luxury non-gaming hotels worldwide
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
Advised Grainger plc on the sale of a portfolio of 1,203 residential home reversion properties located across the UK to Clifden Holdings Limited
Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
Advised the Special Transaction Committee of the Board of Morgans Hotel Group on the transfer of its ownership interests in Delano South Beach and The Light Group to The Yucaipa Companies in exchange for the cancellation of certain securities held by Yucaipa (debt, preferred stock and warrants) together with a $100 million rights offering backstopped by Yucaipa
Advised AvalonBay on its joint acquisition with Equity Residential of the assets and liabilities of Archstone Enterprise LP, an owner of high-quality apartment communities in major markets in the United States, from Lehman Brothers Holdings
Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
Advised Boyd Gaming Corporation, a leading gaming operator in Nevada, the Midwest and South, on the acquisition of Peninsula Gaming, a casino operator of five properties in Kansas, Iowa and Louisiana
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
Advised The Miller Group, the UK’s largest private homebuilder, on the recapitalization of its balance sheet comprising a substantial new equity capital raising and a significant debt for equity swap
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
Advised Heiwa Corporation, a leading provider of pachinko amusement machines, on the tender offer to acquire 80.5% of PGM Holdings K.K., one of the largest golf club owners and operators in Japan, including 64.2% Lone Star Funds’ holding
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
Advised Minerva plc, a property investment and development company, on a recommended offer from a consortium consisting of AREA Property Partners and Delancey Real Estate Asset Management
Advised Boyd Gaming Corporation, a leading gaming operator in Nevada, the Midwest and South, on the acquisition of Imperial Palace Casino Resort and Spa in Biloxi, Mississippi
Advised Centrebet International, a leading International online wagering and gaming operator on the recommended cash offer by Sportingbet plc
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
Advised the 2006 Credit Facility Lenders, the largest class of unsecured debt with claims in excess of $2.8 billion, in connection with the Chapter 11 proceedings of mall REIT GGP, which resulted in cash payoff of the facilities in full
Advised Aevum Limited, an ASX listed owner, operator and developer of retirement villages and aged care facilities on its response to a hostile takeover offer from Stockland Ltd, a global property development and investment management group
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery
Advised term loan and credit facility lenders to the Tishman Speyer partnership holding a portfolio of 28 office buildings in Washington D.C. and the surrounding area on a restructuring which resulted in payoff of the facilities in full
Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company
Advised the shareholders of Camelot – Cadbury, De La Rue, Fujitsu, Royal Mail and Thales – on the sale of their shareholdings in Camelot, the operator of the UK National Lottery, to Ontario Teachers’ Pensions Plan
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company
Advised Minerva plc, a UK real estate development company, on its successful defence following an unsolicited offer from KiFin Limited, a company that makes investments for the benefit of Mr Nathan Kirsh
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
Acted as Joint Financial Adviser to Ladbrokes plc, a leading UK based betting and gaming company, on its rights issue
Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a U.S. based provider of histopathology diagnostic equipment
Advised the Kogan Family on the sale of Oakland Mall, a regional shopping mall in Troy, Michigan anchored by JC Penney, Sears and Macy's
Advised American Financial Realty Trust, a real estate investment trust that acquires properties from and leases properties to regulated financial institutions, on its sale to Gramercy Capital Corp., a commercial real estate specialty finance company
Provided oversight of the process and an informal second opinion to the senior management of Slough Estates plc
Advised Crescent Real Estate Equities Company, a REIT holding a diversified portfolio of office properties, hotels and resorts and luxury residential developments on its sale to Morgan Stanley Real Estate
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries
Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories
Advised Forest City Enterprises, Inc. on the restructuring of its business relationship with its New York City affiliate Forest City Ratner
Advised the independent directors of Reckson, a real estate investment trust specializing in properties located in New York City and the surrounding Tri-State area, on the sale of Reckson to SL Green
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
(selected assets) Advised GDC Properties on its acquisition of a 77.8% interest in a one million square foot Wilmington, Delaware shopping center portfolio previously held by institutional investors in Acadia Realty Trust Fund I
Advised the Special Committee of the Board of Directors and the Board of Directors of LNR Property Corporation, one of the US’ leading real estate investment, finance and management companies, on its sale to Cerberus Capital Management, L.P. and its real estate affiliate, Blackacre Institutional Capital Management, LLC
Advised Regal Cinemas, the largest theatre chain in the United States, on its prepackaged bankruptcy plan and acquisition by The Anschutz Corporation
(subsidiary of Carlson Companies, Inc.)
Advised Carlson Companies, Inc., the owner of the Radisson Hotels brand, on the formation of a $750 million Radisson Hotel acquisition fund, Radisson-Olympus Capital Partners.
Advised TriNet on a stock for stock merger with Starwood Financial, creating a leading player in the specialty real estate finance area
Advised investor group led by Berkshire Realty Chairman, Goldman Sachs and The Blackstone Group on the buyout of Berkshire Realty, a multi-family REIT that owns 82 apartment communities located in Florida, Texas and the Mid-Atlantic and Southeastern U.S.